trending Market Intelligence /marketintelligence/en/news-insights/trending/Gq8GPh8VE25Y0UoxdrgJmg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Genmab, CureVac sign $10M up-front deal to develop mRNA-based therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Genmab, CureVac sign $10M up-front deal to develop mRNA-based therapies

Genmab A/S is partnering with CureVac AG for the research and development of messenger RNA, or mRNA-based antibody products, in a deal worth $10 million upfront.

Messenger RNA is a type of RNA that can be used as a data carrier to tell the body to create proteins to fight disease, the companies said in a Dec. 19 press release.

CureVac will also receive a €20 million equity investment from Genmab as part of the deal. The company will partly fund the development costs of a potential drug candidate up to filing applications for regulatory approvals, after which Genmab will be responsible for the development and commercialization of the therapy. CureVac will be eligible for future milestone payments and tiered royalties on the therapy as well.

Genmab will also have an option for up to three other commercial licenses to CureVac's mRNA technology exercisable within a five-year period. Upon choosing one of these options, Genmab will fund all development and commercialization of the potential treatment, while CureVac will be eligible to receive between $275 million and $368 million in payments.

CureVac is a privately owned German company that develops mRNA therapeutics aimed at fighting a wide range of diseases, including cancer.